SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)

$TCRR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $TCRR alert in real time by email
SC 13G/A 1 tm226094d36_sc13ga.htm SC 13G/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 4)

 

 

TCR2 THERAPEUTICS INC.

 

(Name of Issuer)

 

Common Stock, $0.0001 par value

(Title of Class of Securities)

 

 

87808K106

 

(CUSIP Number)

 

 

December 31, 2021

 

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

  

þRule 13d-1(b)

 

oRule 13d-1(c)

 

oRule 13d-1(d)

   

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 87808K106

 

1

Name of Reporting Person

 

Redmile Group, LLC

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ 

(b) ¨

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

Delaware

 

 

 

number of
shares
beneficially
owned by
each
reporting
person with

 

 

5

Sole Voting Power

 

0

6

Shared Voting Power

 

1,346,058(1) 

7

Sole Dispositive Power

 

0

8

Shared Dispositive Power

 

1,346,058 (1) 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,346,058 (1) 

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

 

11

 

Percent of Class Represented by Amount in Row (9)

 

3.5%(2) 

12

Type of Reporting Person (See Instructions)

 

IA, OO

       

 

(1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of 1,346,058 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

(2) Percentage based on 38,220,444 shares of Common Stock outstanding as of November 2, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 10, 2021 (the “Form 10-Q”).

 

 

 

 

CUSIP No. 87808K106

 

1

Name of Reporting Person

 

Jeremy C. Green

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ 

(b) ¨

3

SEC Use Only

 

 

4

Citizenship or Place of Organization

 

United Kingdom

 

 

 

number of
shares
beneficially
owned by
each
reporting
person with

 

 

5

Sole Voting Power

 

0

6

Shared Voting Power

 

1,346,058 (3

7

Sole Dispositive Power

 

0

8

Shared Dispositive Power

 

1,346,058 (3) 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,346,058 (3)

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11

Percent of Class Represented by Amount in Row (9)

 

3.5%(4)

12

Type of Reporting Person (See Instructions)

 

IN, HC

       

 

(3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 1,346,058 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

(4) Percentage based on 38,220,444 shares of Common Stock outstanding as of November 2, 2021, as reported by the Issuer in the Form 10-Q.

 

 

 

 

Item 1.

 

(a)Name of Issuer

 

TCR2 Therapeutics Inc.

 

(b)Address of Issuer’s Principal Executive Offices

 

100 Binney Street, Suite 710

Cambridge, MA 02142

 

Item 2.

 

(a)Names of Persons Filing

 

Redmile Group, LLC

Jeremy C. Green

 

(b)Address of Principal Business office or, if None, Residence

 

Redmile Group, LLC

One Letterman Drive

Building D, Suite D3-300

 The Presidio of San Francisco

San Francisco, California 94129

 

Jeremy C. Green

c/o Redmile Group, LLC

One Letterman Drive

Building D, Suite D3-300

The Presidio of San Francisco

San Francisco, California 94129

 

  (c)Citizenship

 

Redmile Group, LLC: Delaware

Jeremy C. Green: United Kingdom

 

  (d) Title of Class of Securities

 

Common Stock, $0.0001 par value

 

  (e)CUSIP Number

 

87808K106

 

 

 

 

Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
(b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

 

(c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
(d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
     
(e)x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

(f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
     
(g)x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
(h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
(i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
(j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

(k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

  

Item 4.Ownership.

 

(a)Amount beneficially owned:

 

Redmile Group, LLC – 1,346,058*
Jeremy C. Green – 1,346,058*

 

(b)Percent of class:

 

Redmile Group, LLC – 3.5%**
Jeremy C. Green – 3.5%**

 

(c)Number of shares as to which Redmile Group, LLC has:

 

(i)Sole power to vote or to direct the vote:

 

 0

 

(ii)Shared power to vote or to direct the vote:

 

    1,346,058*

 

(iii)Sole power to dispose or to direct the disposition of:

 

 0

 

(iv)Shared power to dispose or to direct the disposition of:

 

1,346,058*

 

 

 

 

Number of shares as to which Jeremy C. Green has:

 

(i)Sole power to vote or to direct the vote:

 

 0

  

(ii)Shared power to vote or to direct the vote:

 

    1,346,058*

 

(iii)Sole power to dispose or to direct the disposition of:

 

 0

 

(iv)Shared power to dispose or to direct the disposition of:

 

    1,346,058*

 

*Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 1,346,058 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

 

**Percentage based on 38,220,444 shares of Common Stock outstanding as of November 2, 2021, as reported by the Issuer in the Form 10-Q.

 

Item 5.Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

N/A.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

See the response to Item 4.

 

Item 8.Identification and Classification of Members of the Group.

 

N/A

 

Item 9.Notice of Dissolution of Group.

 

N/A

 

Item 10.Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

 

 

SIGNATURE

  

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2022

 

  Redmile Group, LLC  
     
  By: /s/ Jeremy C. Green
    Name: Jeremy C. Green
    Title: Managing Member

  

    /s/ Jeremy C. Green
    Jeremy C. Green  

 

 

 

Get the next $TCRR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TCRR

DatePrice TargetRatingAnalyst
1/19/2022$28.00 → $5.00Buy → Neutral
Goldman
1/13/2022$25.00 → $19.00Buy
HC Wainwright & Co.
11/19/2021$55.00 → $26.00Overweight
Piper Sandler
11/10/2021$8.00 → $7.00Market Perform
SVB Leerink
10/21/2021$18.00 → $8.00Outperform → Mkt Perform
SVB Leerink
9/20/2021$40.00 → $29.00Buy
Truist Securities
9/20/2021$37.00 → $25.00Buy
HC Wainwright & Co.
9/17/2021$45.00 → $11.00Outperform → Neutral
Wedbush
More analyst ratings

$TCRR
Press Releases

Fastest customizable press release news feed in the world

See more
  • TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

    CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. "We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies' complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the w

    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 2,000 shares of TCR2's common stock to one non-executive new hire. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.77, which represents the closing market price

    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) --  TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2's common stock to two non-executive new hires. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.50, which represents the closing mar

    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCRR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TCRR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TCRR
SEC Filings

See more

$TCRR
Leadership Updates

Live Leadership Updates

See more
  • TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer

    CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations. "We are excited to announce Eric Sullivan is joining the TCR2 team as Chief Financial Officer," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "Eric brings a tremendous breadth of financial,

    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

    CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities. "We are pleased to welcome Dr. Rosemary Harrison as our first Chief Business and Strategy Officer at TCR2 as she has proven throughout her career an ability to work closely with multiple commercial function

    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors

    CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to its Board of Directors. Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine. In connection with Dr. Hegde's arrival, Patrick Baeuerle, Ph.D., will be stepping down from the Board of Directors effective August 24, 2021 but will continue to serve TCR2

    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCRR
Financials

Live finance-specific insights

See more
  • Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

    Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapiesFollowing closing of the transaction, cash runway extended into 2026Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined companyCompanies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT)Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts--(Newsfile Corp. - Ma

    $ADAP
    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

    Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT) PHILADELPHIA and OXFORD, U.K. and CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Ada

    $ADAP
    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

    - Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NE

    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCRR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more